Global animal health leader Virbac has unveiled its strategic mid-2026 expansion framework for its companion animal endocrinology and senior canine/feline care portfolios. Driven by an accelerating global trend in pet humanization and increased companion longevity, the company has scaled up its therapeutic and nutritional innovations across Europe, North America, and the Asia-Pacific region.
Hormonal and endocrine disorders represent a primary reason for senior veterinary consultations. Virbac’s commercial strategy focuses on enhancing owner treatment compliance and animal comfort by transitioning traditional, high-stress chronic therapies into seamless, multi-disciplinary care regimens.
Targeted Endocrinology Extensions & Compliance Innovations
To minimize the daily friction points for pet owners managing chronic life-long conditions, Virbac has rolled out specialized galenic and liquid delivery systems tailored to specific metabolic pathologies:
Feline Hyperthyroidism: Multi-Region Liquid Formulation Scale-Up
Building on its strategic acquisition of Thyronorm® (marketed as Felanorm® in the United States), Virbac has successfully deployed its specialized liquid thiamazole/methimazole oral solution across the US, Europe, Australia, and New Zealand.
-
Clinical Advantage: The honey-flavored oral liquid effectively masks the natural bitterness of the active thyroid-inhibiting drug.
-
Precision Titration: Paired with an International Society of Feline Medicine (ISFM) “Easy to Give” award-winning syringe calibrated directly in milligram (mg) increments rather than volume (mL), the formulation minimizes dosing errors and completely eliminates the compliance friction of pilling senior cats.
Canine Hyperadrenocorticism (Cushing’s Syndrome)
Following a successful commercial onboarding across European veterinary channels over the past several quarters, Virbac’s unique galenic formulation for canine Cushing’s syndrome has stabilized market share. The custom-dosed oral therapy simplifies exact titration schedules, helping pet owners consistently suppress excessive cortisol production safely at home.
Canine Hypothyroidism
Virbac continues to anchor its core European endocrine foundation through the distribution of its gold-standard thyroid hormone replacement therapies. The targeted solutions are currently deployed across key Western European veterinary hubs, specifically France and Germany, to restore baselines for vital metabolic functions in dogs.
Transversal Care Model: Linking Nutrition and Medicine
A core element of Virbac’s 2026 commercial outlook is its holistic, cross-category approach to chronic care. Recognizing that systemic endocrine disorders cause cascading biological damage, the company is actively bridging the gap between pharmaceutical regulation and supportive therapies.
Veterinarians are being equipped with integrated care protocols that combine localized hormone regulation with:
-
Advanced Clinical Nutrition: Utilizing the newly refreshed Veterinary HPM® physiological and dietary food ranges to manage secondary clinical concerns, such as lean muscle mass loss, feline obesity, and compromised renal health.
-
Targeted Dermatology Portfolios: Deploying advanced topical treatments to rapidly repair unkempt coats, persistent alopecia, and fragile epidermal skin barriers caused by Cushing’s syndrome or severe thyroid imbalances.
